Sabina Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sabina Ruiz has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Pané
Endocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain
3 shared publications - Antonio Jesús Amor
Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
3 shared publications Antonio Picó
2 shared publicationsBetina Biagetti
2 shared publications- Clara Viñals
Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
2 shared publications Elena Valassi
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
MRI-based radiomics prediction of somatostatin receptor ligand response in acromegaly: an automated pipeline study
Context: Radiomics may capture tumor characteristics predicting therapeutic response. Objective: To develop an MRI-based radiomics pipeline for predicting response to SRLs in acromegaly. Methods: MRI data from 267 subjects across 3 datasets were used to develop an automated tumor detection and segmentation pipeline (Spanish multicenter acromegaly IGTP cohort, n = 81; 2 public datasets, n = 186). The 3-stage pipeline comprised: (1) automated tumor detection (YOLOv8), (2) 3D segmentation (SegResNet), and (3) radiomic feature extraction (PyRadiomics) with supervised classification. Treatment-response radiomics included contrast-enhanced T1-weighted (Ce-T1W1) MRI from 49 patients treated with SRL. SRL response was defined as ≥50% IGF-1 reduction or normalization. Eleven machine-learning classifiers were evaluated using stratified repeated k-fold cross-validation. Results: Automated segmentation achieved a Dice coefficient of 0.795 using combined Ce-T1WI and T2-weighted images (T2WI), decreasing to 0.765 in the acromegaly-specific cohort. The best-performing model was a 3-feature logistic regression classifier, with an out-of-fold AUC of 0.798 (95% CI: 0.671-0.918), balanced accuracy of 0.793, F1-score of 0.815, and correct classification of 39/49 patients (79.6%). Performance improved as the radiomic feature set was reduced from 5 to 2. The most consistent feature was log-sigma-3-0-mm-3D_glcm_ClusterShade, which appeared in 98% of cross-validation folds and contributed most to the model-derived discriminative signal. Conclusion: In this multicenter radiomics study of SRL response prediction in acromegaly, an automated pipeline achieved good discriminative performance (AUC = 0.798). These findings highlight both the promise and the current challenges of radiomics-based treatment prediction.
- 26 August 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
Open AccessMRI-based radiomics prediction of somatostatin receptor ligand response in acromegaly: an automated pipeline study
Context: Radiomics may capture tumor characteristics predicting therapeutic response. Objective: To develop an MRI-based radiomics pipeline for predicting response to SRLs in acromegaly. Methods: MRI data from 267 subjects across 3 datasets were used to develop an automated tumor detection and segmentation pipeline (Spanish multicenter acromegaly IGTP cohort, n = 81; 2 public datasets, n = 186). The 3-stage pipeline comprised: (1) automated tumor detection (YOLOv8), (2) 3D segmentation (SegResNet), and (3) radiomic feature extraction (PyRadiomics) with supervised classification. Treatment-response radiomics included contrast-enhanced T1-weighted (Ce-T1W1) MRI from 49 patients treated with SRL. SRL response was defined as ≥50% IGF-1 reduction or normalization. Eleven machine-learning classifiers were evaluated using stratified repeated k-fold cross-validation. Results: Automated segmentation achieved a Dice coefficient of 0.795 using combined Ce-T1WI and T2-weighted images (T2WI), decreasing to 0.765 in the acromegaly-specific cohort. The best-performing model was a 3-feature logistic regression classifier, with an out-of-fold AUC of 0.798 (95% CI: 0.671-0.918), balanced accuracy of 0.793, F1-score of 0.815, and correct classification of 39/49 patients (79.6%). Performance improved as the radiomic feature set was reduced from 5 to 2. The most consistent feature was log-sigma-3-0-mm-3D_glcm_ClusterShade, which appeared in 98% of cross-validation folds and contributed most to the model-derived discriminative signal. Conclusion: In this multicenter radiomics study of SRL response prediction in acromegaly, an automated pipeline achieved good discriminative performance (AUC = 0.798). These findings highlight both the promise and the current challenges of radiomics-based treatment prediction.
- Open Access
- 8 July 2023
- Published by Wiley in Clinical Endocrinology
- Vol. 99 (4) , 378-385
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly
Objective: Hyperintensity signal in T2‐weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real‐life clinical practice.Design, Patients and Measurements: Retrospective multicentre study including acromegaly patients treated with pasireotide. Adenoma T2‐weighted MRI signal at diagnosis was qualitatively classified as iso‐hyperintense or hypointense. Insulin‐like growth factor (IGF‐I), growth hormone (GH) and tumour volume reduction were assessed after 6 and 12 months of treatment and its effectiveness evaluated according to baseline MRI signal. Hormonal response was considered ‘complete’ when normalization of IGF‐I levels was achieved. Significant tumour shrinkage was defined as a volume reduction of ≥25% from baseline.Results: Eighty‐one patients were included (48% women, 50 ± 1.5 years); 93% had previously received somatostatin receptor ligands (SRLs) treatment. MRI signal was hypointense in 25 (31%) and hyperintense in 56 (69%) cases. At 12 months of follow‐up, 42/73 cases (58%) showed normalization of IGF‐I and 37% both GH and IGF‐I. MRI signal intensity was not associated with hormonal control. 19/51 cases (37%) presented a significant tumour volume shrinkage, 16 (41%) from the hyperintense group and 3 (25%) from the hypointense.Conclusions: T2‐signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF‐I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.
- 8 July 2023
- Published by Wiley in Clinical Endocrinology
- Vol. 99 (4) , 378-385
Open AccessMagnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly
Objective: Hyperintensity signal in T2‐weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real‐life clinical practice.Design, Patients and Measurements: Retrospective multicentre study including acromegaly patients treated with pasireotide. Adenoma T2‐weighted MRI signal at diagnosis was qualitatively classified as iso‐hyperintense or hypointense. Insulin‐like growth factor (IGF‐I), growth hormone (GH) and tumour volume reduction were assessed after 6 and 12 months of treatment and its effectiveness evaluated according to baseline MRI signal. Hormonal response was considered ‘complete’ when normalization of IGF‐I levels was achieved. Significant tumour shrinkage was defined as a volume reduction of ≥25% from baseline.Results: Eighty‐one patients were included (48% women, 50 ± 1.5 years); 93% had previously received somatostatin receptor ligands (SRLs) treatment. MRI signal was hypointense in 25 (31%) and hyperintense in 56 (69%) cases. At 12 months of follow‐up, 42/73 cases (58%) showed normalization of IGF‐I and 37% both GH and IGF‐I. MRI signal intensity was not associated with hormonal control. 19/51 cases (37%) presented a significant tumour volume shrinkage, 16 (41%) from the hyperintense group and 3 (25%) from the hypointense.Conclusions: T2‐signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF‐I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.
- 1 June 2022
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 186 (6) , R79-R92
ENDOCRINE OBESITY: Pituitary dysfunction in obesity
Obesity, the growing pandemic of the 21st century, is associated with multiple organ dysfunction, either by a direct increase in fatty organ content or by indirect modifications related to general metabolic changes driven by a specific increase in biologic products. The pituitary gland is not protected against such a situation. Different hypothalamic–pituitary axes experience functional modifications initially oriented to an adaptive situation that, with years of obesity, turn to maladaptive dynamics that contribute to perpetuating obesity and specific symptoms of their hormonal nature. This paper reviews the recent knowledge on obesity-related pituitary dysfunction and its pathogenic mechanisms and discusses potential therapeutic actions aimed at contributing to ameliorating the complex treatment of severe cases of obesity.
- 1 June 2022
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 186 (6) , R79-R92
ENDOCRINE OBESITY: Pituitary dysfunction in obesity
Obesity, the growing pandemic of the 21st century, is associated with multiple organ dysfunction, either by a direct increase in fatty organ content or by indirect modifications related to general metabolic changes driven by a specific increase in biologic products. The pituitary gland is not protected against such a situation. Different hypothalamic–pituitary axes experience functional modifications initially oriented to an adaptive situation that, with years of obesity, turn to maladaptive dynamics that contribute to perpetuating obesity and specific symptoms of their hormonal nature. This paper reviews the recent knowledge on obesity-related pituitary dysfunction and its pathogenic mechanisms and discusses potential therapeutic actions aimed at contributing to ameliorating the complex treatment of severe cases of obesity.
- Open Access
- 7 April 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 36 (7) , e3323
Insulin resistance is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes
Aim: Although insulin resistance (IR) is a growing trait among type 1 diabetes (T1D) population, its relationship with atherosclerosis has been scarcely studied. We assessed the association between IR indexes and carotid atherosclerosis in T1D, a population at high cardiovascular disease (CVD) risk.Materials and Methods: We evaluated 191 participants with T1D and no prior CVD with at least one of the following criteria: ≥40 years old; diabetic nephropathy; or T1D duration ≥10 years harbouring ≥1 additional CVD risk factor. IR was assessed with the metabolic syndrome (MetS) harmonized definition proposed in 2009 and the estimated glucose disposal rate (eGDR), a T1D‐specific IR surrogate marker (lower values indicating higher IR). Standardized carotid ultrasonography was performed, recording intima‐media thickness (IMT), plaque presence and maximum height of plaque. Comparisons between patients according to their MetS status as well as concerning eGDR values were performed.Results: The participants' median age was 47.4 (41.1‐53.3) years and diabetes duration 25.7 (21.6‐32.5) years. Plaque prevalence was higher in patients with greater IR (49.1%, 29.1% and 20%, P = .001, for any plaque according to decreasing eGDR tertiles). Conversely, no statistically significant higher plaque prevalence was found in participants with MetS. In multivariate analyses (adjusted for general‐ and T1D‐specific risk factors, and statin treatment), MetS was associated with neither IMT nor plaque. On the contrary, eGDR was independently related to ≥2 plaques (P = .018) and maximum plaque height (P < .01).Conclusions: In T1D, IR assessed through eGDR but not by MetS definition was independently associated with plaque burden, a predictor of CVD.
- 7 April 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 36 (7) , e3323
Open AccessInsulin resistance is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes
Aim: Although insulin resistance (IR) is a growing trait among type 1 diabetes (T1D) population, its relationship with atherosclerosis has been scarcely studied. We assessed the association between IR indexes and carotid atherosclerosis in T1D, a population at high cardiovascular disease (CVD) risk.Materials and Methods: We evaluated 191 participants with T1D and no prior CVD with at least one of the following criteria: ≥40 years old; diabetic nephropathy; or T1D duration ≥10 years harbouring ≥1 additional CVD risk factor. IR was assessed with the metabolic syndrome (MetS) harmonized definition proposed in 2009 and the estimated glucose disposal rate (eGDR), a T1D‐specific IR surrogate marker (lower values indicating higher IR). Standardized carotid ultrasonography was performed, recording intima‐media thickness (IMT), plaque presence and maximum height of plaque. Comparisons between patients according to their MetS status as well as concerning eGDR values were performed.Results: The participants' median age was 47.4 (41.1‐53.3) years and diabetes duration 25.7 (21.6‐32.5) years. Plaque prevalence was higher in patients with greater IR (49.1%, 29.1% and 20%, P = .001, for any plaque according to decreasing eGDR tertiles). Conversely, no statistically significant higher plaque prevalence was found in participants with MetS. In multivariate analyses (adjusted for general‐ and T1D‐specific risk factors, and statin treatment), MetS was associated with neither IMT nor plaque. On the contrary, eGDR was independently related to ≥2 plaques (P = .018) and maximum plaque height (P < .01).Conclusions: In T1D, IR assessed through eGDR but not by MetS definition was independently associated with plaque burden, a predictor of CVD.
- 2 April 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 36 (7) , e3320
Steno type 1 risk engine and preclinical atherosclerosis in Mediterranean individuals with type 1 diabetes
Background and aims: Tools to detect type 1 diabetes (T1D) individuals at overt cardiovascular disease (CVD) risk are scarce. We aimed to assess the usefulness of the score ‘Steno Type 1 Risk Engine’ (Steno‐Risk) to identify T1D patients with advanced carotid atherosclerosis.Material and methods: T1D patients without CVD with at least one of the following were included: ≥40 years, diabetic nephropathy, or diabetes duration ≥10 years with ≥1 CVD risk factor. Intima‐media thickness (IMT) and plaque presence (IMT ≥1.5 mm) were assessed by standardized B‐mode ultrasonography. Steno‐Risk was used to estimate 10‐year risk (P < .001 for all). Preclinical atherosclerosis (IMT and plaque) increased in parallel with Steno‐Risk (P < .001). In logistic regression analysis, both age ≥40 years and Steno‐Risk ≥20% were associated with the presence of plaque (OR 4.22 [1.57‐11.36] and 3.79 [1.61‐6.80]; respectively), but only high Steno‐Risk remained independently associated with ≥2 plaques (OR 3.31 [1.61‐6.80]).Conclusion: Steno‐Risk is independently associated with preclinical atherosclerosis. Further studies are needed to ascertain its usefulness in this high‐risk population.
- 2 April 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 36 (7) , e3320
Steno type 1 risk engine and preclinical atherosclerosis in Mediterranean individuals with type 1 diabetes
Background and aims: Tools to detect type 1 diabetes (T1D) individuals at overt cardiovascular disease (CVD) risk are scarce. We aimed to assess the usefulness of the score ‘Steno Type 1 Risk Engine’ (Steno‐Risk) to identify T1D patients with advanced carotid atherosclerosis.Material and methods: T1D patients without CVD with at least one of the following were included: ≥40 years, diabetic nephropathy, or diabetes duration ≥10 years with ≥1 CVD risk factor. Intima‐media thickness (IMT) and plaque presence (IMT ≥1.5 mm) were assessed by standardized B‐mode ultrasonography. Steno‐Risk was used to estimate 10‐year risk (P < .001 for all). Preclinical atherosclerosis (IMT and plaque) increased in parallel with Steno‐Risk (P < .001). In logistic regression analysis, both age ≥40 years and Steno‐Risk ≥20% were associated with the presence of plaque (OR 4.22 [1.57‐11.36] and 3.79 [1.61‐6.80]; respectively), but only high Steno‐Risk remained independently associated with ≥2 plaques (OR 3.31 [1.61‐6.80]).Conclusion: Steno‐Risk is independently associated with preclinical atherosclerosis. Further studies are needed to ascertain its usefulness in this high‐risk population.